COSMETIC / DIRECT CATALOG PRICING
Pal-GHK
Pal-GHK is N-palmitoyl-glycyl-L-histidyl-L-lysine, also named palmitoyl tripeptide-1. PubChem distinguishes it from unmodified GHK and GHK-Cu.
- Format
- Lyophilized research vial
- Listed formats
- 1
- Available now
- 0
- Catalog class
- Cosmetic
- 200 mgPricing by inquiry · AvailableSelect
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
Pal-GHK is N-palmitoyl-glycyl-L-histidyl-L-lysine, also named palmitoyl tripeptide-1. PubChem distinguishes it from unmodified GHK and GHK-Cu.
The cosmetic classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Cosmetic
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- Contact for current availability
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
Pal-GHK is N-palmitoyl-glycyl-L-histidyl-L-lysine, also named palmitoyl tripeptide-1. PubChem distinguishes it from unmodified GHK and GHK-Cu.
- Research covered
- PubChem supplies the standardized identity and sequence annotation. A 12-week eye-cream study included palmitoyl tripeptide-1 together with palmitoyl tetrapeptide-7 and other ingredients, so its results apply only to that multi-ingredient topical formulation and cannot isolate Pal-GHK.
- Important limit
- No evidence located establishes the performance of this catalog's 200 mg raw material. Multi-ingredient topical studies cannot be attributed to Pal-GHK alone, and they do not evaluate a lyophilized research vial.
FACTUAL FAQ
Pal-GHK catalog questions
What formats are currently listed?
200 mg. Current price and stock state appear above.
What did researchers study?
PubChem supplies the standardized identity and sequence annotation. A 12-week eye-cream study included palmitoyl tripeptide-1 together with palmitoyl tetrapeptide-7 and other ingredients, so its results apply only to that multi-ingredient topical formulation and cannot isolate Pal-GHK.
What is the most important evidence limit?
No evidence located establishes the performance of this catalog's 200 mg raw material. Multi-ingredient topical studies cannot be attributed to Pal-GHK alone, and they do not evaluate a lyophilized research vial.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →
